Insulet Corporation · NASDAQ:PODD
Insulet — William Blair 46th Annual Growth Stock Conference (June 2026)
19 slides from Insulet's conference presentation, Jun 3, 2026
Slide 1: William Blair 46th Annual Growth Stock Conference
William Blair 46th Annual Growth Stock Conference Eric Benjamin – EVP, Chief Operating Officer June 3, 2026 Eric Benjamin EVP, Chief Operating Officer 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, source or third-party suppliers on which we are dependent; failure to retain key future operating and financial performance, product success and efficacy, the suppliers; challenges to the futur
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: Insulet presents the above non-GAAP financial measures because management uses • Constant currency revenue growth, which represents the change in revenue them as supplemental measures in assessing the Company’s p
Slide 4: A world where diabetes demands less every day, everywhere.
Vision Mission A world where diabetes Born of empathy, driven by ingenuity, demands less every proven by science, we transform the day, everywhere. lives of people with diabetes. Chloe Podder since 2021 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not water
Slide 5: A global leader in diabetes management
A global leader in diabetes management The first AID system1 FDA- #1 U.S. requested and prescribed AID system2,3 cleared for both type 1 and #1 U.S. new customer starts4 type 2 in the U.S. #1 EU new customer starts4 $2.7B 600K+ 25 2025 revenue Active customers5 Global markets 5
Slide 6: Q1 results and 2026 outlook
Q1 results and 2026 outlook Q1 2026 Performance 2026 Guidance7 Strategic Highlights Revenue Revenue Guidance8 Recent Total Company 33.9%, $761.7M - Second generation Omnipod 5 algorithm now available in the U.S. 30.1% constant currency6 Q2 2026 revenue 20% - 22% - Omnipod 5 now compatible with FSL3+
Slide 7: Large TAM with clear runway for durable growth
Large TAM with clear runway for durable grow Today: $30B+ Developing new markets • Total addressable market11 of ~8M PWDs • ~$6B AID market today with line of sight to ~$9B by 2028 1 2 3 Leverage T1D OUS Broaden into U.S. Expand into viable T1D momentum to launch T2D basal-only opportunity in Asia13
Slide 8: Sustained and profitable growth built on market leadership
Sustained and profitable growth built on market leadership Total revenue ($B) Adj. operating margin6 (%) Adj. EPS6 Free cash flow6 ($M) $2.7 $378 17.6% $4.97 $305 $2.1 14.9% $1.7 12.3% 11.5% $3.24 $1.3 9.5% $2.75 $1.1 $70 $1.30 $0.86 2021 2022 2023 2024 2025 ($4) 2021 2022 2023 2024 2025 2021 2022 2
Slide 9: Winning formula for value creation
2026 –2028 Winning formula for value creation ~20% ~100 bps 25%+ Revenue CAGR in Annual adjusted operating Adjusted EPS6 CAGR constant currency margin6 expansion Strong FCF6 generation • Leading product • Modest gross margin improvement • Under-penetrated • Investment in innovation addressable marke
Slide 10: Continuum of Innovation Meets Diverse Needs of Patients and Providers
Continuum of Innovation Meets Diverse Needs of Patients and Providers 2026 2027 2028 Enhanced algorithm Advanced automation Redefined experience Stronger outcomes Designed for even stronger More accessible AID outcomes with less effort Omnipod 5 Omnipod 6* Fully Closed Loop for T2D* with Algorithm E
Slide 11: Investing in extending our leadership and growth
Investing in extending our leadership and growth 1 Innovation 2 Capabilities 3 Capacity Plan to invest $1B in R&D over Strengthening our competitive moats Expanding global the next 3 years manufacturing capacity • Omnipod 6 Market development • Ongoing automation in Acton • Fully closed loop (T2D) •
Slide 12: Our compelling investment thesis
Our 1 Ample growth runway in large, underpenetrated markets compelling Deep, durable, defensible moats investment 2 across technology, science, manufacturing, thesis access, and brand 3 Robust innovation pipeline to drive adoption and unlock new opportunities 4 Disciplined strategy to develop market
Slide 13: Thank You
Thank You Insulet
Slide 14: Insulet common abbreviations and acronyms
Insulet common abbreviations and acronyms A1C Blood test measures average blood glucose levels over the last 3 months HCP Health Care Provider ADA American Diabetes Association iOS iPhone Operating System AID Automated Insulin Delivery KOL Key Opinion Leader ASP Average Selling Price LRP Long-range
Slide 15: FY 2026 guidance
FY 2026 guidance7 Revenue guidance8 P&L guidance Assumptions & drivers Q2 2026 FY 2026 FY 2026 adjusted FY 2026 adjusted Continued strong Omnipod 5 revenue revenue operating margin9 EPS growth9 adoption globally ~100bps >25% U.S. & International annual 20% - 22% 21% - 23% NCS growth YoY (Previously
Slide 16: Non-GAAP reconciliation — revenue guidance
Non-GAAP reconciliation — revenue guidance Year Ending December 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 20% to 22% —% 20% to 22% International Omnipod 29% to 31% 3% 26% to 28% Total Omnipod 23% to 25% 1% 22% to 24% Drug Delivery ~(50)% —% ~(50)% Total Revenue 22%
Slide 17: Reconciliation of historical Non-GAAP Measures
Reconciliation of historical Non-GAAP Measures $s in Millions 2025 2024 2023 2022 2021 Operating Income $ 473.8 $ 308.9 $ 220.1 $ 37.6 $ 126.0 Operating Margin % 17.5 % 14.9 % 13.0 % 2.9 % 11.5 % Voluntary MDCs14 — — (11.5) 57.9 — Legal costs15 — — — 25.2 — CEO and CFO transition costs16 (2.4) — — 3
Slide 18: Endnotes (1/2)
Endnotes (1/2) Page Title Marker Footnote 5 A global leader in diabetes management 1 Omnipod 5 product specific 5 A global leader in diabetes management 2 Omnipod 5 product specific; Source: dQ&A HCP AID Algorithm Study – May 2025. p.40 n=414 5 A global leader in diabetes management 3 Omnipod 5 prod
Slide 19: Endnotes (2/2)
Endnotes (2/2) Page Title Marker Footnote 7 Large TAM today with clear runway to grow 12 Includes 24 existing international markets and two planned expansion markets 7 Large TAM today with clear runway to grow 13 Includes Japan, China, and South Korea 17 Reconciliation of historical non-GAAP measure
Insulet — William Blair 46th Annual Growth Stock Conference (June 2026) on 6ix